Skip to main content

Table 3 Correlation of LINC01133 and ABHD11-AS1 expression with clinicopathological features in luminal BC patients

From: Expression profiles and functional prediction of long non-coding RNAs LINC01133, ZEB1-AS1 and ABHD11-AS1 in the luminal subtype of breast cancer

Characteristics No. of cases (total: 79) LINC01133 expression level ABHD11-AS1 expression level
Low
N (%)
High
N (%)
P-value Low
N (%)
High
N (%)
P-value
Age at diagnosis (2 missing, n = 77)
 ≤ 40 20 9 (25.0%) 11 (26.8%) 0.86 7 (19.4%) 13 (31.7%) 0.22
 > 40 57 27 (75.0%) 30 (73.2%)   29 (80.6%) 28 (68.3%)  
Tumor size (1 missing, n = 78)
 < 2 cm 23 11 (29.7%) 12 (29.3%) 0.93 9 (23.1%) 14 (35.9%) 0.43
 2–5 cm 41 20 (54.1%) 21 (51.2%)   23 (59.0%) 18 (46.2%)   
 > 5 cm 14 6 (16.2%) 8 (19.5%)   7 (17.9%) 7 (17.9%)  
Tumor subtype (n = 79)
 Luminal A 65 32 (80.0%) 33 (84.6%) 0.59 34 (81.0%) 31 (83.8%) 0.74
 Luminal B 14 8 (20.0%) 6 (15.4%)   8 (19.0%) 6 (16.2%)  
Grade (n = 79)
 1 11 7 (18%) 4 (10.0%) 0.42 5 (12.2%) 6 (15.8%) 0.87
 2 54 24 (61.5%) 30 (75.0%)   29 (70.7%) 25 (65.8%)  
 3 14 8 (20.5%) 6 (15.0%)   7 (17.1%) 7 (18.4%)  
Stage (2 missing, n = 77)
 I 6 2 (5.4%) 4 (10.0%) 0.62 1 (2.4%) 5 (13.9%) 0.16
 II 42 22 (59.4%) 20 (50.0%)    23 (56.1%) 19 (52.8%)  
 III 29 13 (35.2%) 16 (40.0%)   17 (41.5%) 12 (33.3%)  
Pathology of tumors (7 missing, n = 72)
 DCIS 3 2 (5.9%) 1 (2.6%) 0.80 1 (3.0%) 2 (5.1%) 0.85
 LCIS 3 1 (2.9%) 2 (5.3%)   1 (3.0%) 2 (5.1%)  
 IDC 57 28 (82.4%) 29 (76.3%)   28 (85.0%) 29 (74.4%)  
 ILC 4 1 (2.9%) 3 (7.9%)   1 (3.0%) 3 (7.7%)  
 Others 5 2 (5.9%) 3 (7.9%)   2 (6.0%) 3 (7.7%)  
Progesterone receptor (n = 79)
 Negative 10 4 (10.5%) 6 (14.6%) 0.58 4 (9.8%) 6 (15.8%) 0.42
 Positive 69 34 (89.5%) 35 (85.4%)   37 (90.2%) 32 (84.2%)  
Estrogen receptor (n = 79)
 Negative 0 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
 Positive 79 38 (100.0%) 41 (100.0%)    40 (100.0%) 39 (100.0%)  
HER2 (n = 79)
 Negative 70 32 (86.5%) 38 (90.5%) 0.58 37 (90.2%) 33 (86.8%) 0.63
 Positive 9 5 (13.5%) 4 (9.5%)   4 (9.8%) 5 (13.2%)  
  1. Stage grouping is based on American Joint Committee on Cancer (AJCC). Estrogen receptor (ER), progesterone receptor (PR), and Her2/neu classification is based on IHC results. The positive cut-off point is determined according to IHC guideline of American Society of Clinical Oncology (ASCO)
  2. DCIS Ductal Carcinoma in Situ, LCIS Lobular Carcinoma in Situ, IDC Invasive Ductal Carcinoma, ILC Invasive Lobular Carcinoma